MAP2K7 and ovarian carcinoma: Adding MEK/ERK inhibitors to various chemotherapeutic agents [47], including ALDH1A inhibitor [18] and Src inhibitor [22], has been suggested as a way to overcome ovarian cancer therapy resistance.